Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.

Published in: Breast cancer research : BCR (2018)

89Zr-trastuzumab can potentially assess tumor response to dasatinib in HER2+ breast cancer and could be used as a surrogate tool to monitor early changes in Src signaling downstream of HER2.

Keyphrases

pet imaging
tyrosine kinase
epidermal growth factor receptor
positron emission tomography
metastatic breast cancer
chronic myeloid leukemia
computed tomography
combination therapy
replacement therapy
pet ct